ArticleEuropean journal of hospital pharmacy : science and practice2020
The economic burden of metastatic breast cancer in Spain.
Article in European journal of hospital pharmacy : science and practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.PharmacoEconomics · 2022Pooled it
- Clinical and cost outcomes of a polyethylene glycol (PEG)-coated patch versus drainage after axillary lymph node dissection in breast cancer: results from a multicentre randomized clinical trial.The British journal of surgery · 2023Trial
- Reducing breast cancer recurrences with CDK4/6 inhibitor treatment of HR-positive, HER2-negative early stage breast cancer from a societal perspective.Health economics review · 2026Article
- Estimating the societal impact of medical interventions: a case study in metastatic breast cancer.Journal of comparative effectiveness research · 2026Article
- Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025-2035 (Goal 9).Breast (Edinburgh, Scotland) · 2025Review
- Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis.PharmacoEconomics - open · 2025Article
- The economic burden of breast cancer in western Iran: a cross-sectional cost-of-illness study.Journal of health, population, and nutrition · 2025Article
- A systematic literature review on direct and indirect costs of triple-negative breast cancer.Cost effectiveness and resource allocation : C/E · 2023Review
- Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.Current oncology (Toronto, Ont.) · 2023Article
- A systemmatic literature review on indirect costs of women with breast cancer.Cost effectiveness and resource allocation : C/E · 2022Review
- Cancer Survivors' Long-Term Health Service Costs in Queensland, Australia: Results of a Population-Level Data Linkage Study (Cos-Q).International journal of environmental research and public health · 2022Article
- Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer - a Danish register-based study from 2005 to 2016.BMC health services research · 2022Article
- Lifetime Costs of Surviving Cancer-A Queensland Study (COS-Q): Protocol of a Large Healthcare Data Linkage Study.International journal of environmental research and public health · 2020Article
- Development and validation of a sexual relations satisfaction scale in patients with breast cancer - "SEXSAT-Q".Health and quality of life outcomes · 2019Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years. Methods: An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles. Results: The incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2-/HR+, 520 HER2+/HR+, 324 HER2+/HR-, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2-/HR+, 2.82 years for HER2+/HR- and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR-and €94,572 for triple negative patients over 5 years. Conclusions: The economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2-/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.